CAJ | 학술논문

目的：制备替莫唑胺（TMZ）鼻腔脑靶向药物组合，并初步评价其在大鼠C6胶质瘤模型的治疗效果。方法接种C6胶质瘤细胞，得到大鼠胶质瘤模型40只；随机分为4组：空白组、静脉注射TMZ组、口服TMZ组和鼻腔脑靶向药组，每组10只。分别用生理盐水、TMZ静脉注射、灌胃以及鼻腔脑靶向制剂对大鼠C6胶质瘤模型治疗后，观察大鼠的肿瘤体积大小、生存期、病理学的改变。结果 TMZ脑靶向药治疗后肿瘤体积增长明显低于空白组、静脉注射TMZ组和口服TMZ组（12.45±2.49 mm3 vs 60.16±4.12 mm3，33.17±3.56 mm3，35.16±4.36 mm3，P<0.05）。中位生存期鼻腔脑靶向药组较空白组、静脉注射TMZ组和灌胃TMZ组延长（31.0 d vs 20 d，19 d，21.5 d，P<0.05）。HE染色证实各组大鼠均接种了胶质瘤，TMZ鼻腔脑靶向药组较其他各组PCNA表达减少，凋亡增加。结论 TMZ脑靶向药能抑制胶质瘤肿瘤细胞的生长，或可作为治疗胶质瘤新的有效制剂。
목적：제비체막서알（TMZ）비강뇌파향약물조합，병초보평개기재대서C6효질류모형적치료효과。방법접충C6효질류세포，득도대서효질류모형40지；수궤분위4조：공백조、정맥주사TMZ조、구복TMZ조화비강뇌파향약조，매조10지。분별용생리염수、TMZ정맥주사、관위이급비강뇌파향제제대대서C6효질류모형치료후，관찰대서적종류체적대소、생존기、병이학적개변。결과 TMZ뇌파향약치료후종류체적증장명현저우공백조、정맥주사TMZ조화구복TMZ조（12.45±2.49 mm3 vs 60.16±4.12 mm3，33.17±3.56 mm3，35.16±4.36 mm3，P<0.05）。중위생존기비강뇌파향약조교공백조、정맥주사TMZ조화관위TMZ조연장（31.0 d vs 20 d，19 d，21.5 d，P<0.05）。HE염색증실각조대서균접충료효질류，TMZ비강뇌파향약조교기타각조PCNA표체감소，조망증가。결론 TMZ뇌파향약능억제효질류종류세포적생장，혹가작위치료효질류신적유효제제。
Objective To study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts. Methods Forty Wistar rat bearing brain C6 glioma xenograft were randomly divided into 4 groups and treated with physiological saline solution or with TMZ by intravenous injection, gavage or intranasal administration. The tumor size, rat survival time and pathological changes were observed in each group. Results Magnetic resonance imaging showed a significantly reduced volume of glioma in intranasal TMZ group compared with that in the control, intraveneous TMZ injection group and TMZ gavage groups (12.45±2.49 mm3 vs 60.16±4.12, 33.17±3.56, and 35.16±4.36 mm3, respectively, P<0.05). The median survival time of the C6 glioma-bearing rats was also significantly longer in intranasal TMZ group than in the other 3 groups (31.0 days vs 20, 19, and 21.5 days, respectively, P<0.05). In the glioma xenografts, PCNA expression was the lowest and tumor cell apoptosis rate the highest in intranasal TMZ group. Conclusion Intranasal TMZ administration can suppress the growth of C6 glioma in rats and may serve as an effective strategy for glioma treatment.